Desmopressin
Dosages; See below
Combinations; See below
Desmopressin Brands
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| DDAVP | Ferring Pharmaceuticals | Radiance Pharmaceuticals Limited | 100mcg | 30 | Tablet | per tablet | KES 5,200.00 |
| DDAVP | Ferring Pharmaceuticals | Radiance Pharmaceuticals Limited | 200mcg | 30 | Tablet | per tablet | KES 6,905.00 |
| DDAVP | Ferring Pharmaceuticals | Radiance Pharmaceuticals Limited | 4mcg/ml | 10ml | Injection | per ampoule | KES 14,904.00 |
| DDAVP | Ferring Pharmaceuticals | Radiance Pharmaceuticals Limited | 0.1mg | 5ml | Nasal spray/drops | KES 6,825,00 | |
| Desmocip | Cipla Ltd. | Lords Healthcare Ltd. | 5ml | Nasal spray/drops | KES 1,850 |
| Desmopressin More Info | |
|---|---|
| Mode Of Action | Desmopressin (1-desamino-8-D-arginine vasopressin) is a modified form of the normal human hormone arginine vasopressin. It is a synthetic replacement for antidiuretic hormone, the hormone that reduces urine production during sleep. Desmopressin binds to V2 receptors in renal collecting ducts, increasing water resorption. It also stimulates release of factor VIII from endothelial cells due to stimulation of the V1a receptor. |
| Drug Indication | Hemophilia A and von Willebrand's Disease (Type I), diabetes Insipidus, bedwetting |
| Side Effects | Headache, nausea, mild abdominal cramps and vulval pain Injection can produce local erythema, swelling or burning pain; occasional facial flushing; anaphylaxis |
| Dosage | Hemophilia A and von Willebrand's Disease (Type I):
DDAVP Injection 4 mcg/mL is administered as an intravenous infusion at a dose of 0.3 mcg DDAVP/kg body weight diluted in sterile physiological saline and infused slowly over 15 to 30 minutes. In adults and children weighing more than 10 kg, 50 mL of diluent is recommended; in children weighing 10 kg or less, 10 mL of diluent is recommended. Diabetes Insipidus: administered sc or IV: 4 mcg/mL dosage must be determined for each patient and adjusted according to the pattern of response. Response should be estimated by two parameters: adequate duration of sleep and adequate, not excessive, water turnover.The usual dosage range in adults is 0.5 mL (2.0 mcg) to 1mL (4.0 mcg) daily, usually in two divided doses. |
| Drug Category | DRUGS ACTING ON GENITO-URINARY SYSTEM |
| Drug Sub-Category | Other genito-urinary acting drugs |